8-K: Lisata Licenses Peptide for Catalent ADC Platform

Lisata Therapeutics entered a non-exclusive license agreement with Catalent, Inc. for its certepetide in antibody drug conjugates, potentially yielding up to $10.5 million in milestones and future revenue sharing.

Summary

• Lisata Therapeutics, Inc. (the Company) entered into a worldwide Non-Exclusive License Agreement with Catalent, Inc. on October 8, 2025.
• The agreement grants Catalent a non-exclusive license to use Lisata's novel iRGD cyclic peptide, certepetide, as an antibody drug conjugate (ADC) payload within Catalent's SMARTag ADC platform.
• Catalent will assume full responsibility for all research, development, and commercialization costs associated with the licensed technology.
• Lisata is eligible to receive pre-determined development milestone payments totaling up to $10.5 million.
• The Company is also eligible for tiered revenue sharing on future sales and/or partnerships, subject to specified royalty reductions.
• Lisata will receive a portion of any sublicense consideration Catalent obtains from granting sublicenses or similar rights under the agreement.
• The agreement remains in effect on a product-by-product and country-by-country basis until the end of the royalty term.
• Either party can terminate the agreement for material breach or bankruptcy/insolvency of the other party, subject to notice and cure provisions.
• Catalent has the right to terminate the entire agreement at any time with at least thirty (30) days prior written notice.
• Catalent has granted Lisata a right of first negotiation (ROFN) for a license if Catalent initiates an organized out-licensing process for an asset resulting from this agreement.

Sentiment

Score: 7

Explanation: The non-exclusive license agreement with Catalent is a positive development, providing potential milestone payments and future revenue streams while shifting development costs to Catalent. However, the non-exclusive nature and Catalent's unilateral termination right introduce some caveats, preventing a higher score.

Positives

• Potential to receive up to $10.5 million in development milestone payments, providing non-dilutive capital.
• Eligibility for tiered revenue sharing on future sales and partnerships, creating a long-term revenue stream.
• Catalent assumes full responsibility for research, development, and commercialization costs, reducing Lisata's financial burden and risk.
• Validation of Lisata's certepetide technology through a partnership with a major industry player like Catalent.
• The agreement includes a right of first negotiation for Lisata on any out-licensed assets resulting from the collaboration.

Negatives

• The license granted to Catalent is non-exclusive, meaning Lisata can license the same technology to other parties, potentially leading to competition.
• Catalent retains the right to terminate the entire agreement at any time with only thirty days' notice, introducing uncertainty.
• Future revenue sharing is subject to specified royalty reductions, which could impact the ultimate financial upside for Lisata.

Risks

• Catalent's ability to terminate the agreement at any time with 30 days' notice poses a risk to the continuity of the partnership and future revenue streams.
• The success of development and commercialization of ADC products using certepetide is largely dependent on Catalent's efforts and resources.
• The non-exclusive nature of the license means that Catalent's efforts may not be solely focused on this specific application, or Lisata may face competition from other licensees.
• Achievement of milestone payments and revenue sharing is contingent on successful development, regulatory approval, and commercialization, which are inherently uncertain in drug development.

Future Outlook

The agreement provides a pathway for Lisata's certepetide technology to be integrated into Catalent's SMARTag ADC platform, potentially leading to new therapeutic developments and future revenue streams through milestone payments and tiered revenue sharing. It also offers a right of first negotiation for Lisata on any resulting out-licensed assets from Catalent.

Management Comments

• David J. Mazzo, PhD, President & Chief Executive Officer, signed the report on behalf of Lisata Therapeutics, Inc.

Industry Context

This licensing agreement positions Lisata Therapeutics within the rapidly growing antibody drug conjugate (ADC) market, a significant area of focus in oncology and targeted therapies. By partnering with Catalent, a leading contract development and manufacturing organization (CDMO) with its established SMARTag platform, Lisata gains access to advanced development capabilities and broader market reach for its novel peptide payload. This collaboration reflects a broader industry trend of specialized biotech companies partnering with larger entities to de-risk and accelerate drug development, particularly for complex modalities like ADCs.

Comparison to Industry Standards

• The structure of milestone payments and tiered royalties is a standard financial model for licensing agreements in the biopharmaceutical industry, particularly for early-stage assets or platform technologies.
• The assumption of research, development, and commercialization costs by the licensee (Catalent) is typical for such partnerships, especially when the licensor (Lisata) is a smaller biotech focused on intellectual property development.
• The inclusion of a right of first negotiation (ROFN) is a common protective clause for licensors, ensuring they have an opportunity to participate in future out-licensing of derived assets, though specific comparable deals are not detailed in the filing.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through future milestone payments, revenue sharing, and validation of the company's intellectual property.
• Employees: No direct immediate impact mentioned, but successful development could lead to future growth opportunities.
• Customers (future patients): Potential for new and improved antibody drug conjugate therapies to address unmet medical needs.

Next Steps

• The full text of the Non-Exclusive License Agreement is intended to be filed as an exhibit to Lisata's Annual Report on Form 10-K for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

The non-exclusive license agreement with Catalent represents a positive strategic move for Lisata Therapeutics, validating its certepetide technology and providing a pathway for potential milestone payments and future revenue without incurring significant R&D costs. However, the non-exclusive nature of the agreement and Catalent's right to terminate at any time introduce elements of uncertainty. While the deal is favorable, it's an early-stage partnership, and its full financial impact is yet to be realized. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor the progress of the partnership and future financial disclosures.

Keywords

Lisata Therapeutics, Catalent, Non-Exclusive License, iRGD cyclic peptide, certepetide, Antibody Drug Conjugate, ADC, SMARTag, Biopharmaceutical, Drug Development, Milestone Payments, Revenue Sharing, Intellectual Property